MedPath
HSA Approval

DEFUZIN CREAM 2% W/W

SIN15620P

DEFUZIN CREAM 2% W/W

DEFUZIN CREAM 2% W/W

February 1, 2019

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.
Licence HolderAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CREAM

TOPICAL

Medical Information

D06AX01

fusidic acid

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

FUSIDIC ACID (MICRONISED)

2.00% w/w

Fusidic acid

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DEFUZIN CREAM 2% W/W - HSA Approval | MedPath